Feb 07, 2024 / 04:30PM GMT
Vamil Divan - Guggenheim Securities, LLC - Analyst
I think we're ready to get started here. Thanks so much, everyone, again for joining us for our Annual Biotech Conference. I'm Vamil Divan, one of the biopharma analyst here at Guggenheim. Happy to have our next company here at Savara, a company we actually just recently launched coverage on a few months back.
We have Matt Pauls, the CEO; Ray Pratt, the CMO; we also have, Anne Erickson, Chief Business Officer in the back. (Conference Instructions)
But I thought maybe I'll just start with you. And just giving up for those people that may be less familiar with the story, a little bit of background in Savara, and some of the key recent events, obviously there's a big data readout coming up here, which we'll talk about that, but the path to get us to this point we're hopeful this will kick things off.
Questions and Answers:
Matthew Pauls - Savara Inc - President, Chief Executive OfficerYaah sure. So I'm Matt Pauls, Chair of the Board of Directors, and CEO of Savara. Thanks for the